{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T04:12:36Z","timestamp":1788581556195,"version":"build-2803163510"},"reference-count":31,"publisher":"Japanese Society of Internal Medicine","issue":"17","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026,9,1]]},"DOI":"10.2169\/internalmedicine.6293-25","type":"journal-article","created":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T22:08:03Z","timestamp":1769897283000},"page":"2358-2363","source":"Crossref","is-referenced-by-count":0,"title":["Successful Treatment of Synchronous Double Lung and Colon Cancers Using Immune Checkpoint Inhibitors"],"prefix":"10.2169","volume":"65","author":[{"given":"Shuichi","family":"Matsuoka","sequence":"first","affiliation":[{"name":"Respiratory Medicine Division, Matsue Red Cross Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Tokuyasu","sequence":"additional","affiliation":[{"name":"Respiratory Medicine Division, Matsue Red Cross Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsunori","family":"Arai","sequence":"additional","affiliation":[{"name":"Respiratory Medicine Division, Matsue Red Cross Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromitsu","family":"Sakai","sequence":"additional","affiliation":[{"name":"Respiratory Medicine Division, Matsue Red Cross Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chika","family":"Esumi","sequence":"additional","affiliation":[{"name":"Pathology Division, Matsue Red Cross Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Yamasaki","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine and Rheumatology, Department of Multidisciplinary Internal Medicine, School of Medicine, Faculty of Medicine, Tottori University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Vogt A, Schmid S, Heinimann K, et al. Multiple primary tumours: challenges and approaches, a review. ESMO open 2: e000172, 2017.","DOI":"10.1136\/esmoopen-2017-000172"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Brahmer JR, Lee JS, Ciuleanu TE, et al. Five-year survival outcomes with nivolumab plus ipilimumab versus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer in CheckMate 227. J Clin Oncol 41: 1200-1212, 2023.","DOI":"10.1200\/JCO.22.01503"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Johnson ML, Cho BC, Luft A, et al. Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer: the phase III POSIDON Study. J Clin Oncol 41: 1213-1227, 2023.","DOI":"10.1200\/JCO.22.00975"},{"key":"4","unstructured":"4. Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 Study. J Clin Oncol 38: 1-10, 2020."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Rodr\u00edguez MR, Biedma BA, Rodr\u00edguez P\u00e9rez I, Romeo JA. Elucidating the role of <i>KRAS<\/i>, <i>NRAS<\/i>, and <i>BRAF<\/i> mutations and microsatellite instability in colorectal cancer via next-generation sequencing. Cancers 17: 2071, 2025.","DOI":"10.3390\/cancers17132071"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Shiraishi Y, Hakozaki T, Nomura S, et al. A multicenter, randomized phase III study comparing platinum combination chemotherapy plus pembrolizumab with platinum combination chemotherapy plus nivolumab and ipilimumab for treatment-na\u00efve advanced non-small cell lung cancer without driver gene alterations: JCOG2007 (NIPPON Study). Clin Lung Cancer 23: e285-e288, 2022.","DOI":"10.1016\/j.cllc.2021.10.012"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Armer MH. Multiple neoplasms, single primaries, and patient survival. Cancer Manag Res 6: 119-134, 2014.","DOI":"10.2147\/CMAR.S57378"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Kurishima K, Miyazaki K, Watanabe H, et al. Lung cancer patients with synchronous colon cancer. Mol Clin Oncol 8: 137-140, 2018.","DOI":"10.3892\/mco.2017.1471"},{"key":"9","unstructured":"9. Friedrich RE. Primary and second primary cancer in 649 patients with malignancies of the maxillofacial region. Anticancer Res 27: 1805-1818, 2007."},{"key":"10","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/s12885-015-1276-z","volume":"15","author":"A Kawazoe","year":"2015","unstructured":"10. Kawazoe A, Shitara K, Fukuoka S, et al. A retrospective observational study of clinicopathological features of <i>KRAS<\/i>, <i>NRAS<\/i>, <i>BRAF<\/i>, and <i>PIK3CA<\/i> mutations in Japanese patients with metastatic colorectal cancer. BMC Cancer 15: 285, 2015.","journal-title":"BMC Cancer","ISSN":"https:\/\/id.crossref.org\/issn\/1471-2407","issn-type":"print"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Cremolini C, Antoniotti C, Lonardi S, et al. Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO. Ann Oncol 22: 1528-1534, 2018.","DOI":"10.1093\/annonc\/mdy140"},{"key":"12","unstructured":"12. Goldstraw P, Chansky K, Crowley J, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (Eighth) edition of the TNM classification for lung cancer. J Thorac Oncol 11: 39-51, 2016."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Wang L, Liu L, Zhao J, Yu X, Su C. Clinical significance and molecular annotation for PD-L1 negative advanced non-small cell lung cancer with sensitivity to responsive to dual PD-1\/CTLA-4 blockade. Immunotargets Ther 13: 435-445, 2024.","DOI":"10.2147\/ITT.S476040"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Katsurada M, Nagano T, Tachihara M, et al. Baseline tumor size as a predictive and prognostic factor of immune checkpoint inhibitor therapy for non-small cell lung cancer. Anticancer Res 39: 815-825, 2019.","DOI":"10.21873\/anticanres.13180"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Hopkins AM, Kichenadasse G, McKinnon RA, Rowland A, Sorich MJ. Baseline tumor size and survival outcomes in lung cancer patients treated with immune checkpoint inhibitors. Semin Oncol 46: 380-384, 2019.","DOI":"10.1053\/j.seminoncol.2019.10.002"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Li F, Tian C, Wang Y, et al. Prognostic significance of peripheral and tumor-infiltrating lymphocytes in newly diagnosed stage III\/IV non-small-cell lung cancer. Front Med (Lausanne) 11: 1349178, 2024.","DOI":"10.3389\/fmed.2024.1349178"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Cheng L, Creasy T, Pilataxi F, et al. Effects of combination treatment with durvalumab plus tremelimumab on the tumor microenvironment in non-small-cell lung cancer. Cancer Immunol Immunother 71: 1167-1181, 2022.","DOI":"10.1007\/s00262-021-03065-5"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Uehara Y, Hakozaki T, Kitadai R, et al. Association between the baseline tumor size and outcomes of patients with non-small cell lung cancer treated with first-line immune checkpoint inhibitor monotherapy or in combination with chemotherapy. Transl Lung Cancer Res 11: 135-149, 2022.","DOI":"10.21037\/tlcr-21-815"},{"key":"19","doi-asserted-by":"publisher","unstructured":"19. Garon EB, Cho BC, Luft A, et al. Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON). Lung Cancer 186: 107422, 2023.","DOI":"10.1016\/j.lungcan.2023.107422"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Garon EB, Cho BC, Luft A, et al. A brief report of durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer: outcomes by tumor PD-L1 expression in the Phase 3 POSEIDON study. Clin Lung Cancer 25: 266-273, 2024.","DOI":"10.1016\/j.cllc.2024.03.003"},{"key":"21","unstructured":"21. Nojadeh JN, Sharif SB, Sakhinia E. Microsatellite instability in colorectal cancer. EXCLI J 17: 159-168, 2018."},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Herman JG, Umar A, Polyak K, et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA 95: 6870-6875, 1998.","DOI":"10.1073\/pnas.95.12.6870"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Fari\u00f1a-Sarasqueta A, van Lijnschoten G, Moerland E, et al. The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. Ann Oncol 21: 2396-2402, 2010.","DOI":"10.1093\/annonc\/mdq258"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Gavin PG, Colangelo LH, Fumagalli D, et al. Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value. Clin Cancer Res 18: 6531-6541, 2012.","DOI":"10.1158\/1078-0432.CCR-12-0605"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Howitt BE, Shukla SA, Sholl LM, et al. Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1. JAMA Oncol 1: 1319-1323, 2015.","DOI":"10.1001\/jamaoncol.2015.2151"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Andr\u00e9 T, Shiu KK, Kim TW, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med 383: 2207-2218, 2020.","DOI":"10.1056\/NEJMoa2017699"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Andr\u00e9 T, Shiu KK, Kim TW, et al. Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study. Ann Oncol 36: 277-284, 2025.","DOI":"10.1016\/j.annonc.2024.11.012"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Oh CR, Kim JE, Hong YS, et al. Phase II study of durvalmab monotherapy in patients with previously treated microsatellite instability-high\/mismatch repair-deficient or POLE-mutated metastatic or unresectable colorectal cancer. Int J Cancer 150: 2038-2045, 2022.","DOI":"10.1002\/ijc.33966"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Andr\u00e9 T, Elez E, Cutsem V, et al. Nivolumab plus ipilimumab in microsatellite-instability-high metastatic colorectal cancer. N Engl J Med 391: 2014-2026, 2024.","DOI":"10.1056\/NEJMoa2402141"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Andr\u00e9 T, Elez E, Lenz HJ, et al. Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomized, open-label, phase 3 trial. Lancet 405: 383-395, 2025.","DOI":"10.1016\/S0140-6736(24)02848-4"},{"key":"31","unstructured":"31. Raimondi A, Lonardi S, Murgioni S, et al. Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONO. Ann Oncol 36: 285-296, 2025."}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/17\/65_6293-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T03:31:11Z","timestamp":1788579071000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/17\/65_6293-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":31,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.6293-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"article-number":"6293-25"}}